Lipoplatin (cisplatin liposomal) / Regulon - LARVOL DELTA

Evaluation of the antiproliferative effect of histone deacetylase inhibitor (HDACi) CI-994 and Liposomal Cisplatin LipoPlatin on MCF-7 and MDA-MB-231 cells as monotherapy and combined therapy. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "The application of a combination of CI-994 and Lipoplatin for each cell line has shown that while there was a significant decrease in cell viability, mitotic index (MI), and BrdU labeling index (LI), there was a significant increase in AI. Consequently, it was thought that combined treatments were more efficient than single medication applications and decreased the cell prognosis with a synergistic and additive impact."

Journal • Monotherapy • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Husain Discusses Role of Osimertinib in Non–Small Cell Lung Cancer (Targeted Oncology) - "During a Targeted Oncology™ Case-Based Roundtable™ event, Hatim Husain, MD, discussed data on targeted adjuvant therapy for non-small cell lung cancer....HUSAIN: The rapid recommendation update from the ASCO [American Society of Clinical Oncology] guidelines states that for patients with completely resected stage IB NSCLC, adjuvant osimertinib [Tagrisso] is recommended for patients with an EGFR mutation that has an exon 19 deletion or L858R. Adjuvant cisplatin [Platinol]-based chemotherapy or atezolizumab [Tecentriq] are not indicated for use in this patient group. For patients with stage IIA, IIB, or IIIA disease, adjuvant cisplatin-based chemotherapy is recommended."

Media quote

Comparison of Cytotoxic and Ototoxic Effects of Lipoplatin and Cisplatin in Neuroblastoma In Vivo Tumor Model. (PubMed, J Int Adv Otol) - "For the treatment of neuroblastoma, the use of lipoplatin seems to be beneficial in reducing side effects of cisplatin. We recommend that the mechanism of these properties of lipoplatin should be evaluated in further studies."

Journal • Preclinical • Neuroblastoma • Oncology • Solid Tumor • NOS2 • SOD2

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - P1/2; N=50; Active, not recruiting; Sponsor: Oncology Venture; Trial completion date: Dec 2020 ➔ Apr 2021; Trial primary completion date: Dec 2020 ➔ Apr 2021

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Genetic Disorders • Genito-urinary Cancer • Oncology • Prostate Cancer • Skin Cancer • Solid Tumor

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - P1/2; N=50; Active, not recruiting; Sponsor: Oncology Venture; Recruiting ➔ Active, not recruiting; Trial completion date: Sep 2020 ➔ Dec 2020; Trial primary completion date: Sep 2020 ➔ Dec 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • Genetic Disorders • Genito-urinary Cancer • Oncology • Prostate Cancer • Skin Cancer • Solid Tumor

Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells. (PubMed) - Cancer Invest - "The combined effects of siRNA-EphA2 and Lipoplatin were determined. We report that silencing EphA2 significantly enhanced the cellular sensitivity of lung tumor and MPM cells to Lipoplatin and maybe a potential therapy for lung cancer."

Journal • Biosimilar • Mesothelioma • Non Small Cell Lung Cancer • Oncology

The latest advances of Cisplatin liposomal formulations: essentials for preparation and analysis. (PubMed, Expert Opin Drug Deliv) - "There have been much efforts for improving Cisplatin delivery to the site of action via liposomes both in research and clinical trials such as SPI-077®, Liplacis®, and Lipoplatin®.Areas covered: In this review, we have discussed about Cisplatin and its liposomal formulations, focusing on different preparation methods and analysis approaches such as atomic absorption, mass spectroscopy, UV, electrochemical methods, and emphasizing on HPLC as one of the accurate and specific methods for determination of Cisplatin species and also measurement of total platinum by derivation.Expert Opinion: Liposome of Cisplatin have offered potential beneficial aspects over Cisplatin formulation. Cisplatin resistance is another challenge which should be prevented by higher loading capacity. Charge dependent interactions should also be highly considered especially in the preparation step."

Journal

Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy. (PubMed, Sci Rep) - "Consequently, RAPTA-T pre-treatment followed by the application of cisplatin or liposomal cisplatin (Lipoplatin) leads to increased levels of the cytotoxin in the tumor and enhanced mesothelioma growth inhibition. We demonstrate that the vascular changes induced by RAPTA-T are related, in part, to the inhibition of poly-(ADP-ribose) polymerase 1 (PARP-1) which is associated to tumor vascular stabilization. These findings suggest novel therapeutic implications for RAPTA-T to create conditions for superior drug uptake and efficacy of approved cytotoxic anti-cancer drugs in malignant pleural mesothelioma and potentially other chemoresistant tumors."

Journal

Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity. (PubMed, J Int Adv Otol) - "LIPO showed less toxic effects in the HEI-OC1 cells compared to CDDP at anti-tumoral doses."

Journal

Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview. (PubMed, Artif Cells Nanomed Biotechnol) - "Aroplatin™, Lipoplatin™ and SPI-077 are PEGylated liposome-based nano-formulations that are still under clinical trials. The extensive literature from different electronic databases covers the different nano-delivery systems that are developed for cisplatin. This review critically emphasizes on the recent advancement, development, innovations and updated literature reported for different carrier systems for CDDP."

Journal

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - P1/2; N=50; Recruiting; Sponsor: Oncology Venture; Trial completion date: May 2019 ➔ Sep 2020; Trial primary completion date: May 2019 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date

Data on cytotoxic pattern of cholesterol analogs for lung adenocarcinoma cells. (PubMed, Data Brief) - "Some FDA-approved anticancer drugs (i.e., Lipoplatin and Myocet) are conjugated to Cho moieties to improve their pharmacokinetic properties, cellular uptake and target specificity [2]. We performed theoretical calculations of the biophysicochemical properties, and viability assays in a range of 5-100 μM in A549 cells of these Cho analogs. We used ChemSketch and ChemSpider to determine physical properties, and GraphPad Prism 8 software for the data analysis to determine the inhibitory concentrations at 50% (IC) of each compound."

Journal

PDT-lipo: Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies (clinicaltrials.gov) - P1; N=1; Terminated; Sponsor: Centre Hospitalier Universitaire Vaudois; N=20 ➔ 1; Trial completion date: Jun 2019 ➔ Aug 2018; Recruiting ➔ Terminated; Trial primary completion date: Dec 2016 ➔ Aug 2018; Drug supply issue

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination